Obesity, once regarded as a lifestyle issue, has now escalated into a pressing global health crisis. By 2035, an estimated 1.53 billion adults globally are projected to be living with obesity (BMI ≥30 kg/m2). When combined with the overweight (BMI ≥25 to 30 kg/m2) adult population, the total number is expected to reach 3.3 billion - representing over 54% of the world's adult population. The financial impact is equally significant, with these conditions projected to reduce the global economy by more than US$4 trillion annually by 2035, equivalent to nearly 3% of global GDP.

In response, the pharmaceutical industry has undergone rapid transformation. What was once a niche market has become one of the fastest-growing sectors in healthcare, driven by scientific advancements, innovative therapies, and increasing demand. As new treatments emerge and the market expands, the future of obesity care is being reshaped, offering more effective solutions for weight management and metabolic health.

In 2020, global spending on anti-obesity medications (AOMs) stood at approximately US$3 billion. By 2024, that figure had soared to US$30+ billion - a more than  tenfold increase in just four years. Given the current trend and the pace of innovation in the disease area, the market is expected to sustain its explosive growth well into the future. Between 2024 and 2034, the global AOM market is expected to grow at a CAGR of 13–15% and the total market size is expected to reach  approximately US$130 billion. Biologics are leading the way in the obesity drug market, with GLP-1 and GIP receptor agonists holding the major share. However, non-biologics are expected to regain some market share in the forecast period as the market diversifies and new treatment options emerge.

The obesity market is transforming fast—are you ready? Download the article to uncover key drivers, pipeline trends, and strategic insights that can shape your next move in metabolic health.